Payload Information

General Information of This Payload
Payload ID
PAY0WENAC
Name
seco-MED-A
Synonyms
Seco-MED-A
   Click to Show/Hide
Target Human deoxyribonucleic acid (hDNA)
 Target Info 
Structure
Formula
C35H33ClN6O4
Isosmiles
CN1CCN(C(=O)Oc2cc3c(c4ccccc24)C(CCl)CN3C(=O)c2cc3cc(NC(=O)c4ccc(N)cc4)ccc3[nH]2)CC1
InChI
InChI=1S/C35H33ClN6O4/c1-40-12-14-41(15-13-40)35(45)46-31-18-30-32(27-5-3-2-4-26(27)31)23(19-36)20-42(30)34(44)29-17-22-16-25(10-11-28(22)39-29)38-33(43)21-6-8-24(37)9-7-21/h2-11,16-18,23,39H,12-15,19-20,37H2,1H3,(H,38,43)
InChIKey
XHPMXBJDPYCCKO-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
637.14
Polar area
124
Complexity
46
xlogp Value
5.8846
Heavy Count
46
Rot Bonds
5
Hbond acc
6
Hbond Donor
3
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BMS-936561 [Phase 1 (discontinued)]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data stable disease (SD)
69%
Patients Enrolled
Eligible patients must have ECOG 0-2 and meet tumor-specific criteria: ccRCC patients must have advanced/recurrent disease failing ≥1 prior therapy; B-NHL patients must have relapsed/refractory disease failing ≥1 prior therapy. All subjects must have measurable disease (unidimensional for ccRCC, bidimensional for B-NHL) and provide CD70+ tumor tissue (archived/fresh). Key exclusions include prior anti-CD70 therapy, severe mAb hypersensitivity, active CNS lymphoma, infections, bleeding disorders, active autoimmune disease requiring immunosuppression, or substance abuse.

   Click to Show/Hide
Administration Dosage
Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
Related Clinical Trial
NCT Number NCT00944905  Phase Status PHASE1
Clinical Description
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Primary Endpoint
The study evaluates the safety profile of MDX-1203 and determines the maximum tolerated dose (MTD) with assessment conducted over up to 17 treatment cycles.
Other Endpoint
Biomarker analysis includes assessment of CD70+ tumor incidence in the target population, evaluated during the screening phase.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT00944905  Phase Status Phase 1
Clinical Description
A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.
Experiment 3 Reporting the Activity Date of This ADC [3]
Patients Enrolled
Advanced or recurrent clear cell renal cell carcinoma (ccRCC) or relapsed or refractory B-non Hodgkin lymphoma (NHL), life expectancy of 12 weeks; ECOG performance status of 0-2; measurable disease by RECIST 1.1 criteria for ccRCC and by IWG 2007 criteria for B-NHL as well as adequate hematologic, renal and liver function parameters.
Administration Dosage
0.50, 1.00, 2.00, 4.00, 8.00, 15.00 mg/kg administered every 21 days in a 42 day cycle for a maximum of 17 cycles, IV.
Related Clinical Trial
NCT Number NCT00944905  Phase Status Phase 1
Clinical Description
A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.
Primary Endpoint
The highest best tolerated dose and the recommended dose for future studies was 8 mg/kg dose.There was no MTD determined during the acute toxicity assessment window according to protocol-defined DLT according to protocol-defined DLT. There was disease stabilization in 18 of 26 patients (69.23%) without correlation with received dose.
References
Ref 1 Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Ref 2 A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
Ref 3 First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62.